These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 4514339)

  • 21. [Therapeutic association of L-dopa and an inhibitor of peripheral decarboxylase in Parkinsonism. Preliminary results].
    De Divitiis E; Cerillo A; Tata MR; Decina A
    Acta Neurol (Napoli); 1973; 28(2):208-12. PubMed ID: 4709076
    [No Abstract]   [Full Text] [Related]  

  • 22. Recent advances in the treatment of Parkinsonism with drugs.
    Rinne UK
    Acta Neurol Scand Suppl; 1972; 51():59-103. PubMed ID: 4576076
    [No Abstract]   [Full Text] [Related]  

  • 23. Failure of vitamin B6 to reverse the L-dopa effect in patients on a dopa decarboxylase inhibitor.
    Klawans HL; Ringel SP; Shenker DM
    J Neurol Neurosurg Psychiatry; 1971 Dec; 34(6):682-6. PubMed ID: 5158783
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [10 years of L-DOPA therapy of Parkinson's syndrome].
    Birkmayer W
    Wien Klin Wochenschr; 1971 Apr; 83(13):221-7. PubMed ID: 4254333
    [No Abstract]   [Full Text] [Related]  

  • 25. Parkinsonian syndromes. Treatment by association of L-dopa plus decarboxylase inhibitor.
    Gauthier G; Juge O; Birchler A
    Eur Neurol; 1974; 11(3):133-57. PubMed ID: 4839098
    [No Abstract]   [Full Text] [Related]  

  • 26. A year's comparison of treatment of patients with parkinson's disease with levodopa combined with carbidopa versus treatment with levodopa alone.
    Marsden CD; Parkes JD; Rees JE
    Lancet; 1973 Dec; 2(7844):1459-62. PubMed ID: 4129310
    [No Abstract]   [Full Text] [Related]  

  • 27. The action of L(-)-dopa on baroreflexes in Parkinsonism.
    Reid JL; Calne DB; George CF; Vakil SD
    Clin Sci; 1972 Dec; 43(6):851-9. PubMed ID: 4646277
    [No Abstract]   [Full Text] [Related]  

  • 28. Treatment of Parkinson's disease with L-DOPA and an association L-DOPA plus a DOPA decarboxylase inhibitor.
    Fazio C; Agnoli A; Casacchia M; Reitano M; Ruggieri S; Barba C; Volante F
    Z Neurol; 1972; 202(4):347-55. PubMed ID: 4117654
    [No Abstract]   [Full Text] [Related]  

  • 29. [2-year experiences with a combination treatment of Parkinsonism with L-dopa and a decarboxylase inhibitor (Benserazid, Ro 4-4602)].
    Birkmayer W; Linauer W; Mentasti M; Riederer P
    Wien Med Wochenschr; 1974 Jun; 124(22):340-4. PubMed ID: 4275492
    [No Abstract]   [Full Text] [Related]  

  • 30. [Advantages of the combination therapy (L-Dopa and decarboxylase inhibitors) in parkinsonism].
    Gattringer B; Steinhäusl H
    Wien Med Wochenschr; 1972 Jun; 122(25):369-71. PubMed ID: 4558132
    [No Abstract]   [Full Text] [Related]  

  • 31. Levodopa and pressor amine sensitivity in parkinsonism.
    Reid JL; Calne DB; George CF; Vakil SD
    Clin Pharmacol Ther; 1972; 13(3):400-6. PubMed ID: 5026378
    [No Abstract]   [Full Text] [Related]  

  • 32. [Decarboxylase inhibitor given in combination with l-dopa. A new therapeutic principal in parkinsonism].
    Dietrichson P
    Tidsskr Nor Laegeforen; 1973 Oct; 93(28):2113-5. PubMed ID: 4590070
    [No Abstract]   [Full Text] [Related]  

  • 33. Ro 4-4602 and levodopa in the treatment of Parkinsonism.
    Miller EM; Wiener L
    Neurology; 1974 May; 24(5):482-6. PubMed ID: 4857107
    [No Abstract]   [Full Text] [Related]  

  • 34. [Results of the treatment of Parkinson's diseases with carbidopa and L-Dopa].
    Cáceres AF
    Rev Fac Cienc Med Cordoba; 1974; 32(2):161-74. PubMed ID: 4619691
    [No Abstract]   [Full Text] [Related]  

  • 35. [Treatment of Parkinson's disease with L-dopa and with a combination of L-dopa and dopa-decarboxylase inhibitor].
    Agnoli A; Casacchia M; Reitano M; Ruggieri S; Barba C; Zamponi A
    Minerva Med; 1972 Dec; 63(89):4853-61. PubMed ID: 4566743
    [No Abstract]   [Full Text] [Related]  

  • 36. [L-dopa therapy of Parkinson's syndrome. Comparison of pure L-dopa and the combination preparation L-dopa and decarboxylase inhibitor].
    Görlich J; Markus E
    Dtsch Med Wochenschr; 1972 Aug; 97(34):1246-8. PubMed ID: 5048316
    [No Abstract]   [Full Text] [Related]  

  • 37. Levodopa combined with MK 486 (L-alpha methyldopahydrazine)--a peripheral decarboxylase inhibitor in Parkinson's disease.
    Andrews CJ; Somerville B
    Med J Aust; 1974 Mar; 1(12):429-32. PubMed ID: 4598384
    [No Abstract]   [Full Text] [Related]  

  • 38. [Dopaminergic control of the diencephalo-pituitary axis for somatotropin secretion].
    Cavagnini F; Pontiroli AE; Raggi U; Peracchi M; Malinverni A
    Folia Endocrinol; 1973 Dec; 26(6):483-9. PubMed ID: 4801258
    [No Abstract]   [Full Text] [Related]  

  • 39. On the mechanism of the nullification of CNS effects of L-DOPA by pyridoxine in Parkinsonian patients.
    Pfeiffer R; Ebadi M
    J Neurochem; 1972 Sep; 19(9):2175-81. PubMed ID: 5072392
    [No Abstract]   [Full Text] [Related]  

  • 40. Levodopa in the treatment of Parkinsonism.
    Cotzias GC
    JAMA; 1971 Dec; 218(13):1903-8. PubMed ID: 5171066
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.